Biotech News

AngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026

AngioDynamics (ANGO)AngioDynamics2026-06-25 13:46 ESTEarnings

LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 23, 2025-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today

Open original release

Related news

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics to Present at the Leerink Partners Global Healthcare Conference

View all latest news

AngioDynamics

AngioDynamics is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

ANGOAngioDynamics2026-06-26 07:22 EST

AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)

ANGOAngioDynamics2026-06-26 07:22 EST

AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect

ANGOAngioDynamics2026-06-26 07:22 EST

AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

ANGOAngioDynamics2026-06-26 07:22 EST

AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer

ANGOAngioDynamics2026-06-26 07:22 EST

AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States